• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

计算方法在药物发现中用于鉴定靶向蛋白质相互作用的潜在抑制剂。

Computational approaches for identifying potential inhibitors on targeting protein interactions in drug discovery.

机构信息

Department of Biotechnology, Bhupat and Jyoti Mehta School of Biosciences, Indian Institute of Technology Madras, Chennai, Tamil Nadu, India.

Department of Pharmaceutical Engineering, Vinayaka Mission's Kirupananda Variyar Engineering College, Vinayaka Mission's Research Foundation (Deemed to be University), Salem, Tamil Nadu, India.

出版信息

Adv Protein Chem Struct Biol. 2020;121:25-47. doi: 10.1016/bs.apcsb.2019.11.013. Epub 2020 Jan 13.

DOI:10.1016/bs.apcsb.2019.11.013
PMID:32312424
Abstract

In the era of big data, the interplay of artificial and human intelligence is the demanding job to address the concerns involving exchange of decisions between both sides. Drug discovery is one of the key sources of the big data, which involves synergy among various computational methods to achieve a clinical success. Rightful acquisition, mining and analysis of the data related to ligand and targets are crucial to accomplish reliable outcomes in the entire process. Novel designing and screening tactics are necessary to substantiate a potent and efficient lead compounds. Such methods are emphasized and portrayed in the current review targeting protein-ligand and protein-protein interactions involved in various diseases with potential applications.

摘要

在大数据时代,人工智能和人类智能的相互作用是解决涉及双方决策交流的关键任务。药物发现是大数据的主要来源之一,它涉及各种计算方法的协同作用,以实现临床成功。在整个过程中,合法获取、挖掘和分析与配体和靶点相关的数据对于获得可靠的结果至关重要。需要设计和筛选新的策略来证实有效的先导化合物。本综述重点介绍和描述了目前涉及各种疾病的蛋白质-配体和蛋白质-蛋白质相互作用的潜在应用的新方法。

相似文献

1
Computational approaches for identifying potential inhibitors on targeting protein interactions in drug discovery.计算方法在药物发现中用于鉴定靶向蛋白质相互作用的潜在抑制剂。
Adv Protein Chem Struct Biol. 2020;121:25-47. doi: 10.1016/bs.apcsb.2019.11.013. Epub 2020 Jan 13.
2
Computational Approaches Towards Kinases as Attractive Targets for Anticancer Drug Discovery and Development.计算方法在激酶作为抗癌药物发现和开发的有吸引力的靶点中的应用。
Anticancer Agents Med Chem. 2019;19(5):592-598. doi: 10.2174/1871520618666181009163014.
3
3D-QSAR pharmacophore-based virtual screening, molecular docking and molecular dynamics simulation toward identifying lead compounds for NS2B-NS3 protease inhibitors.基于3D-QSAR药效团的虚拟筛选、分子对接和分子动力学模拟以鉴定NS2B-NS3蛋白酶抑制剂的先导化合物。
J Recept Signal Transduct Res. 2017 Oct;37(5):481-492. doi: 10.1080/10799893.2017.1358283. Epub 2017 Jul 31.
4
Influence of Amino Acid Mutations and Small Molecules on Targeted Inhibition of Proteins Involved in Cancer.氨基酸突变和小分子对癌症相关蛋白靶向抑制的影响。
Curr Top Med Chem. 2019;19(6):457-466. doi: 10.2174/1568026619666190304143354.
5
Discovery of selective dengue virus inhibitors using combination of molecular fingerprint-based virtual screening protocols, structure-based pharmacophore model development, molecular dynamics simulations and in vitro studies.采用基于分子指纹的虚拟筛选方案组合、基于结构的药效团模型开发、分子动力学模拟和体外研究发现选择性登革热病毒抑制剂。
J Mol Graph Model. 2018 Jan;79:88-102. doi: 10.1016/j.jmgm.2017.10.010. Epub 2017 Oct 24.
6
Identification of dengue viral RNA-dependent RNA polymerase inhibitor using computational fragment-based approaches and molecular dynamics study.使用基于片段的计算方法和分子动力学研究鉴定登革病毒RNA依赖性RNA聚合酶抑制剂
J Biomol Struct Dyn. 2016 Jul;34(7):1512-32. doi: 10.1080/07391102.2015.1081620. Epub 2015 Oct 20.
7
Discovery of new selective cytotoxic agents against Bcl-2 expressing cancer cells using ligand-based modeling.基于配体的建模方法发现针对表达 Bcl-2 的癌细胞的新型选择性细胞毒性药物。
Chem Biol Interact. 2016 Apr 25;250:12-26. doi: 10.1016/j.cbi.2016.03.006. Epub 2016 Mar 5.
8
Virtual screening of eighteen million compounds against dengue virus: Combined molecular docking and molecular dynamics simulations study.针对登革病毒的1800万种化合物的虚拟筛选:分子对接与分子动力学模拟相结合的研究
J Mol Graph Model. 2016 May;66:99-107. doi: 10.1016/j.jmgm.2016.03.008. Epub 2016 Mar 25.
9
Structure activity relationship (SAR) and quantitative structure activity relationship (QSAR) studies showed plant flavonoids as potential inhibitors of dengue NS2B-NS3 protease.构效关系(SAR)和定量构效关系(QSAR)研究表明,植物黄酮类化合物是登革热NS2B-NS3蛋白酶的潜在抑制剂。
BMC Struct Biol. 2018 Apr 19;18(1):6. doi: 10.1186/s12900-018-0084-5.
10
Computational insight into dengue virus NS2B-NS3 protease inhibition: A combined ligand- and structure-based approach.基于配体和结构的方法计算洞察登革热病毒 NS2B-NS3 蛋白酶抑制作用。
Comput Biol Chem. 2018 Dec;77:261-271. doi: 10.1016/j.compbiolchem.2018.09.010. Epub 2018 Sep 13.

引用本文的文献

1
Peptide Inhibitor Assay for Allocating Functionally Important Accessible Sites Throughout a Protein Chain: Restriction Endonuclease EcoRI as a Model Protein System.用于在整个蛋白质链中定位功能重要可及位点的肽抑制剂分析:限制性内切核酸酶EcoRI作为模型蛋白质系统
BioTech (Basel). 2024 Dec 30;14(1):1. doi: 10.3390/biotech14010001.
2
Fragment-based Drug Discovery Strategy and its Application to the Design of SARS-CoV-2 Main Protease Inhibitor.基于片段的药物发现策略及其在 SARS-CoV-2 主蛋白酶抑制剂设计中的应用。
Curr Med Chem. 2024;31(38):6204-6226. doi: 10.2174/0109298673294251240229070740.
3
Assessing the potential of NS2B/NS3 protease inhibitors biomarker in curbing dengue virus infections: vs. approach.
评估 NS2B/NS3 蛋白酶抑制剂生物标志物在抑制登革病毒感染方面的潜力:基于结构与基于配体方法的比较。
Front Cell Infect Microbiol. 2023 Feb 14;13:1061937. doi: 10.3389/fcimb.2023.1061937. eCollection 2023.
4
Approaches for the Design and Optimization of Interfering Peptides Against Protein-Protein Interactions.针对蛋白质-蛋白质相互作用的干扰肽的设计与优化方法
Front Mol Biosci. 2021 Apr 28;8:669431. doi: 10.3389/fmolb.2021.669431. eCollection 2021.
5
Fragment tailoring strategy to design novel chemical entities as potential binders of novel corona virus main protease.片段剪裁策略以设计新型化学实体作为新型冠状病毒主要蛋白酶的潜在结合剂。
J Biomol Struct Dyn. 2021 Jul;39(10):3733-3746. doi: 10.1080/07391102.2020.1771424. Epub 2020 Jun 1.